Citadel Advisors’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-109,200
| Closed | -$986K | – | 14353 |
|
|
2025
Q4 | $986K | Buy |
109,200
+65,400
| +149% | +$489K | ﹤0.01% | 7422 |
|
|
2025
Q3 | $136K | Buy |
43,800
+800
| +2% | +$2.12K | ﹤0.01% | 11612 |
|
|
2025
Q2 | $92K | Buy |
43,000
+26,800
| +165% | +$43.3K | ﹤0.01% | 11407 |
|
|
2025
Q1 | $18.6K | Sell |
16,200
-28,200
| -64% | -$48.4K | ﹤0.01% | 13195 |
|
|
2024
Q4 | $97.2K | Buy |
44,400
+19,100
| +75% | +$43.3K | ﹤0.01% | 11526 |
|
|
2024
Q3 | $55.2K | Sell |
25,300
-2,900
| -10% | -$6.67K | ﹤0.01% | 11802 |
|
|
2024
Q2 | $65.1K | Sell |
28,200
-6,700
| -19% | -$27.8K | ﹤0.01% | 11460 |
|
|
2024
Q1 | $192K | Buy |
34,900
+21,300
| +157% | +$97.4K | ﹤0.01% | 10387 |
|
|
2023
Q4 | $33.6K | Buy |
13,600
+6,200
| +84% | +$58.9K | ﹤0.01% | 12173 |
|
|
2023
Q3 | $257K | Sell |
7,400
-6,300
| -46% | -$218K | ﹤0.01% | 9446 |
|
|
2023
Q2 | $449K | Sell |
13,700
-400
| -3% | -$13.8K | ﹤0.01% | 8181 |
|
|
2023
Q1 | $472K | Sell |
14,100
-7,300
| -34% | -$284K | ﹤0.01% | 8432 |
|
|
2022
Q4 | $702K | Buy |
21,400
+6,600
| +45% | +$195K | ﹤0.01% | 7537 |
|
|
2022
Q3 | $517K | Buy |
+14,800
| New | +$328K | ﹤0.01% | 8387 |
|
Other funds holding VTYX
Citadel Advisors's VTYX Position: Q1 2026 in Review
Citadel Advisors sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,563,611 shares — an estimated $14.1M sold.
Citadel Advisors first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $124M in Q4 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Citadel Advisors reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 1,563,611 Ventyx Biosciences shares in Q1 2026, an estimated $14.1M.
- Citadel Advisors first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Citadel Advisors's Ventyx Biosciences position peaked at $124M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.